Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS)
CUSIP: 221015100
Q3 2020 13F Holders as of 30 Sep 2020
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 91,091,040
- Total 13F shares
- 17,216,699
- Share change
- -3,225,708
- Total reported value
- $69,036,016
- Put/Call ratio
- 1.5%
- Price per share
- $4.01
- Number of holders
- 33
- Value change
- -$11,684,715
- Number of buys
- 13
- Number of sells
- 19
Quarterly Holders Quick Answers
What is CUSIP 221015100?
CUSIP 221015100 identifies CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 221015100:
Top shareholders of CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
|
Company |
7.4%
|
6,767,584
|
$18,408,000 | — | 30 Jun 2020 | |
| ADAMS STREET PARTNERS LLC |
13F
|
Company |
3.6%
|
3,275,616
|
$8,910,000 | — | 30 Jun 2020 | |
| Novo Holdings A/S |
13F
|
Company |
3.2%
|
2,927,560
|
$7,963,000 | — | 30 Jun 2020 | |
| BVF INC/IL |
13F
|
Company |
1.9%
|
1,742,112
|
$4,739,000 | — | 30 Jun 2020 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.3%
|
1,192,742
|
$3,244,000 | — | 30 Jun 2020 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.1%
|
1,031,900
|
$2,807,000 | — | 30 Jun 2020 | |
| EcoR1 Capital, LLC |
13F
|
Company |
0.81%
|
737,612
|
$2,006,000 | — | 30 Jun 2020 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.63%
|
574,088
|
$1,561,000 | — | 30 Jun 2020 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.48%
|
438,383
|
$1,193,000 | — | 30 Jun 2020 | |
| CHI Advisors LLC |
13F
|
Company |
0.4%
|
364,132
|
$990,000 | — | 30 Jun 2020 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.34%
|
310,482
|
$844,000 | — | 30 Jun 2020 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.2%
|
181,755
|
$494,000 | — | 30 Jun 2020 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.16%
|
144,362
|
$392,000 | — | 30 Jun 2020 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.15%
|
133,700
|
$364,000 | — | 30 Jun 2020 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.13%
|
114,280
|
$311,000 | — | 30 Jun 2020 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.09%
|
84,918
|
$231,000 | — | 30 Jun 2020 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.09%
|
78,634
|
$214,000 | — | 30 Jun 2020 | |
| Hikari Power Ltd |
13F
|
Company |
0.07%
|
60,959
|
$166,000 | — | 30 Jun 2020 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.06%
|
50,776
|
$138,000 | — | 30 Jun 2020 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.04%
|
39,171
|
$106,000 | — | 30 Jun 2020 | |
| Puissance Capital Management LP |
13F
|
Company |
0.04%
|
38,010
|
$103,000 | — | 30 Jun 2020 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.04%
|
36,880
|
$100,000 | — | 30 Jun 2020 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.03%
|
26,852
|
$73,000 | — | 30 Jun 2020 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.03%
|
26,418
|
$72,000 | — | 30 Jun 2020 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.02%
|
15,519
|
$42,000 | — | 30 Jun 2020 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
15,042
|
$41,000 | — | 30 Jun 2020 | |
| RAYMOND JAMES TRUST N.A. |
13F
|
Company |
0.01%
|
13,158
|
$36,000 | — | 30 Jun 2020 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.01%
|
11,641
|
$32,000 | — | 30 Jun 2020 | |
| BARCLAYS PLC |
13F
|
Company |
0%
|
2,209
|
$6,000 | — | 30 Jun 2020 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
1,854
|
$5,000 | — | 30 Jun 2020 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
1,000
|
$3,000 | — | 30 Jun 2020 | |
| UBS Group AG |
13F
|
Company |
0%
|
719
|
$2,000 | — | 30 Jun 2020 | |
| MEEDER ASSET MANAGEMENT INC |
13F
|
Company |
0%
|
608
|
$2,000 | — | 30 Jun 2020 | |
| Manchester Capital Management LLC |
13F
|
Company |
0%
|
215
|
$1,000 | — | 30 Jun 2020 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
211
|
$1,000 | — | 30 Jun 2020 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
4
|
$11 | — | 30 Jun 2020 |
Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) as of Q3 2020
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2020 vs Q2 2020 Across Filers
| Investor | Q2 2020 Shares | Q3 2020 Shares | Share Diff | Share Chg % | Q2 2020 Value $ | Q3 2020 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.